Merck's efinopegdutide shows improvement in liver fibrosis without worsening steatohepatitis

MRK•2026-11-09

Merck said its Phase 2b trial found efinopegdutide improved liver fibrosis without worsening steatohepatitis in adults with MASH and stage 2-3 fibrosis. The drug also showed significant MASH resolution without fibrosis worsening at 52 weeks.

Merck's efinopegdutide shows improvement in liver fibrosis without worsening steatohepatitis

1. Trial results

Related News

Presidio partners with F5 to secure AI deployment for financial institutions

Olin publishes CA voluntary carbon market disclosures

Prospect Capital presents portfolio update showing first-lien share rises to 71.5%

geniosAI raises $19.1 million in seed and Series A funding from FactSet, Zoom, General Catalyst

Fed's Barkin says there is no base case for December meeting